Development of a new trend conjugate vaccine for the prevention of Klebsiella pneumoniae

Infectious Disease Reports

Volumn 4, Issue 2, 2012, Pages 128-133

  Ahmad, Tarek A ^a   Haroun, Medhat ^a   Hussein, Ahmad A ^a   El Ashry, El Sayed H ^b   El Sayed, Laila H ^c  

^a ALEXANDRIA UNIVERSITY   (Egypt)

^b Alexandria University Faculty Of Science   (Egypt)

^c ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Conjugate vaccines; Isobutyric acid; K. pneumonia; Lipo polysaccharides

Indexed keywords

BACTERIAL O ANTIGEN OUTER MEMBRANE PROTEIN CONJUGATE VACCINE; KLEBSIELLA VACCINE; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BIOMASS PRODUCTION; BLOODSTREAM INFECTION; BODY TEMPERATURE; CONTROLLED STUDY; DECREASED APPETITE; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG POTENCY; DRUG PURITY; DRUG SAFETY; DRUG STABILITY; FEMALE; HOSPITAL INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; KLEBSIELLA PNEUMONIAE INFECTION; NONHUMAN; PLACENTAL TRANSFER; RABBIT; SEPTICEMIA; TOXICITY TESTING; URETHRITIS; URINARY TRACT INFECTION; VACCINATION; VACCINE PRODUCTION;

EID: 84975795246     PISSN: None     EISSN: 20367449     Source Type: Journal    
DOI: 10.4081/idr.2012.e33     Document Type: Article

References (39)

1. Neuhauser MM, Weinstein RA, Rydman R, et al. Antibiotic resistance among Gramnegative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003;289:885-8.
2. Hanberger H, Garcia-Rodriguez JA, Gobernado M, et al. Antibiotic susceptibility among aerobic Gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU study groups. JAMA 1999;281:67-71.
3. Kim YK, Pai H, Lee HJ, et al. Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother 2002;46:1481-91.
4. Bryan CS, Reynolds KL, Brenner ER. Analysis of 1,186 episodes of Gram-negative bacteraemia in non-university hospitals: the effects of antimicrobial therapy. Rev Infect Dis 1983;5:629-38.
5. Young LS. Nosocomial infections in the immunocompromised adult. Am J Med 1981; 70:398-404.
6. McGowan JE Jr, Barnes MW, Finland M. Bacteraemia at Boston City Hospital: occurrence and mortality during 12 selected years (1935-1972), with special reference to hospital-acquired cases. J Infect Dis 1975;132:316-35.
7. Ahmad TA. Construction and evaluation of a conjugate vaccine for the prevention of sepeticemia. Alexandria: Alexandria University; 2012.
8. Doebbeling BN. Epidemics: identification and management. In: Wenzel RP. Prevention and control of nosocomial infections. 2nd ed. Baltimore, Md: The Williams & Wilkins Co; 1993. pp. 177-206.
9. Podschun R, Ullmann U. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev 1998;11:589-603.
10. Merino S, Camprubí S, Albertí S, et al. Mechanisms of Klebsiella pneumoniae resistance to complement-mediated killing. Infect Immun 1992;60:2529-35.
11. Ernst JD. Toward the development of antibacterial vaccines: report of a symposium and workshop. Organizing committee. Clin Infect Dis 1999;29:1295-302.
12. Yadav V, Sharma S, Harjai K, et al. Lipopolysaccharide-mediated protection against Klebsiella pneumoniae-induced lobar pneumonia: intranasal vs. intramuscular route of immunization. Folia Microbiol (Praha) 2005;50:83-6.
13. Chhibber S, Bajaj J. Polysaccharide-ironregulated cell surface protein conjugate vaccine: its role in protection against Klebsiella pneumoniae-induced lobar pneumonia. Vaccine 1995;13:179-84.
14. Chhibber S, Wadhwa S, Yadav V. Protective role of liposome incorporated lipopolysaccharide antigen of Klebsiella pneumoniae in a rat model of lobar pneumonia. Jpn J Infect Dis 2004;57:150-5.
15. Gershoni JM, Roitburd-Berman A, Siman-Tov DD, et al. Epitope mapping: the first step in developing epitope-based vaccines. BioDrugs 2007;21:145-56.
16. Chhibber S, Rani M, Vanashree Y. Immunoprotective potential of polysaccharidetetanus toxoid conjugate in Klebsiella pneumoniae induced lobar pneumonia in rats. Indian J Exp Biol 2005;43:40-5.
17. Clements A, Jenney AW, Farn JL, et al. Targeting subcapsular antigens for prevention of Klebsiella pneumoniae infections. Vaccine 2008;26:5649-53.
18. Ahmad TA, El-Sayed LH, Haroun M, et al. Development of immunization trials against Klebsiella pneumoniae. Vaccine 2012;30:2411-20.
19. El-Sayed LH, Haroun M, Hussein A, et al. Screening of novel epitopes in Klebsiella pneumoniae, as target for vaccine design. Int J Immunol Stud (in press).
20. Hansen DS, Mestre F, Alberti S, et al. Klebsiella pneumoniae lipo-polysaccharide O typing: revision of prototype strains and O-group distribution among clinical isolates from different sources and countries. J Clin Microbiol 1999;37:56-62.
21. Domenico P, Johanson WG Jr, Strauss DC. Lobar pneumonia in rats produced by clinical isolates of Klebsiella pneumoniae. Infect Immun 1982;37:327-35.
22. Laemmli UK. Cleavage of structural proteins during the assembly of the head bacteriophage T4. Nature (Lond) 1970;227:680-5.
23. Karlyshev AV, McCrossan MV, Wren BW. Demonstration of polysaccharide capsule in campylobacter jejuni using electron microscopy. Infect Immun 2001;69:5921-4.
24. Dubois M, Gilles KA, Hamilton JK, et al. Colorimetric method for the determination of sugars and related substances. Anal Chem 1956;28:350-6.
25. Preston A, Peterson BO, Duus JØ, et al. Complete stuctures of Bordetella bronchiseptica and Bordetella parapertussis lipopolysaccharides. J Biol Chem. 2006; 281:18135-44.
26. Caroff MG, Karibian D. Several uses for isobutyric acid-ammonium hydroxide solvent in endotoxin analysis. Appl Environ Microbiol 1990;56:1957-9.
27. Marr N, Novikov A, Hajjar AM, et al. Variability in the lipooligosaccharide structure and endotoxicity among Bordetella pertussis strains. J Infect Dis. 2010;202: 1897-906.
28. Fujita Y, Mori I, Kitano S. Color reaction between pyrogallol red-molybdenum (VI) complex and protein. Bunseki Kagaku 1983;32:E379-86.
29. Russell JA. Management of sepsis. N Engl J Med 2006;355:1699-713.
30. Songa W, Condrona S, Moccab BT, et al. Local and humoral immune responses against primary and repeat Neisseria gonorrhoeae genital tract infections of 17??-estradiol-treated mice. Vaccine 2008;26: 5741-51.
31. McFarland J. The nephelometer. JAMA 1907;49:1176-8.
32. Dominico P, Schwartz S, Cunha B. Reduction of capsular polysaccharide production in Klebsiella pneumoniae by sodium salicylate. Infect Immun 1989;57:3778-82.
33. Vinogradov E, Frirdich E, LL M, et al. Eluicidation of the structure of the linkage region between core and polysaccharide O chain and identification of the residues at the non-reducing termini of the O chains. J Biol Chem 2002;227:25070-81.
34. El-Hamidi A, Tirsoaga A, Novikov A, et al. Microextraction of bacterial lipid A: easy and rapid method for mass spectrometric characterization J Lipid Res 2005;46:1773-8.
35. Caroff M, Deprun C, Richards JC, Karibian D. Structural characterization of the lipid A of Bordetella pertussis 1414 endotoxin. J Bacteriol 1994;176:5156-9.
36. Hay FC, Westwood OMR. Practical immunology. 4th ed. Oxford, UK: Blackwell Science Ltd; 2002.
37. Cerviño M, Figueras L, Martín S, et al. Specific humoral response and effect on rectal temperature of two clostridial vaccines in lambs. Vet Rec 2011;168:458-62.
38. Hunter K. Inhaled and swallowed foreign bodies. Ulster Med J 1946;15:96-102.
39. Rauly I, Goetsch L, Haeuw JF, et al. Carrier properties of a protein derived from outer membrane protein A of Klebsiella pneumoniae. Infect Immun 1999;67:5547-51.